Armata Pharmaceuticals, Inc. (ARMP) Research

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology enterprise with a global focus on creating specialized bacteriophage therapeutics. Its primary objective is to tackle infections that have developed resistance to standard antibiotics. The company's innovative treatments are developed utilizing its exclusive bacteriophage-based technology platform. Within its product pipeline are several significant candidates: AP-SA02, designed for the treatment of Staphylococcus aureus bacteremia; AP-PA02, targeting Pseudomonas aeruginosa; and AP-PA03, intended to address pneumonia. Additionally, Armata has forged a collaborative agreement with Merck & Co. to further the development of synthetic bacteriophage candidates aimed at specific, yet unrevealed, infectious disease agents. The company's main offices are located in Marina del Rey, California.

Market snapshot

Symbol
ARMP
Price
$7.08
Day change
+0.28%
Market cap
$259.9M
P/E ratio
-0.92x
52-week range
1.81-16.34
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$15.00

Peer companies

  • C4 Therapeutics, Inc. (CCCC)
  • Codexis, Inc. (CDXS)
  • Genfit S.A. (GNFT)
  • Insight Molecular Diagnostics Inc. (IMDX)
  • Innate Pharma S.A. (IPHA)
  • Neonc Technologies Holdings, Inc. (NTHI)
  • Nuvectis Pharma, Inc. (NVCT)
  • OmniAb, Inc. (OABI)

Recent insider activity

  • Gilmer Daniel B. — A-Award (51280 shares) on 2026-04-24
  • Gilmer Daniel B. — trade (0 shares) on 2026-04-24
  • Kyme Pierre — F-InKind (1030 shares) on 2026-03-14
  • Birx Deborah — F-InKind (4919 shares) on 2026-03-14
  • Kramer Robin — A-Award (25640 shares) on 2026-03-09

Open Armata Pharmaceuticals, Inc. (ARMP) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.